|
Oct 3
|
High Growth Tech Stocks To Watch In October 2024
|
|
Oct 3
|
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
|
|
Sep 30
|
Brookfield reaffirms its interest in Grifols, ask more time for analysis, sources say
|
|
Sep 25
|
Sector Update: Health Care Stocks Fall Late Afternoon
|
|
Sep 19
|
Grifols Investor Group With 7.7% Holding Seeks Seat on Board
|
|
Sep 10
|
Grifols Holders Call on Family, Brookfield to Offer ‘Fair Price’
|
|
Sep 3
|
Grifols Postpones Capital Markets Day Amid Potential Takeover
|
|
Aug 29
|
Brookfield Courts Sovereign Funds to Join Grifols Takeover Bid
|
|
Jul 29
|
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
|
|
May 9
|
Short Seller Gains on Grifols Bet That Tripped Elliott Spinout
|
|
Apr 19
|
Grifols 2023 Annual Report on Form 20-F filed with the SEC
|
|
Apr 18
|
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
|
|
Apr 14
|
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
|
|
Apr 10
|
Grifols Plans First Bond Sale Since Short Seller Attack
|
|
Apr 4
|
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
|
|
Mar 21
|
Grifols’ Financials Have No Big Errors, Spanish Regulator Says
|
|
Mar 8
|
Health Care Roundup: Market Talk
|
|
Mar 8
|
UPDATE 2-Europe's STOXX 600 logs weekly gains, US jobs data in focus
|
|
Mar 6
|
Spanish Healthcare Firm Grifols Hit With New Gotham City's Short Report, Faces Questions Regarding Transparency, Integrity, Ethical Conduct
|
|
Jan 18
|
ECB Asks Banks for Details About Exposure to Spain’s Grifols
|